In this review, a summary of our current understanding of squamous cell carcinoma of the anus (SCCA) and the advances in our knowledge of SCCA regarding screening, prevention, the role of the immune system, current treatment and the potential for novel 
with radiation, which results in a high level of disease control for small early cancers.
Preservation of the anal sphincter is achieved in the majority, although anorectal function is often impaired. Although evidence from prospective studies to support a change in the treatment strategy is lacking, patients with 
INTRODUCTION
Squamous cell carcinoma of the anus (SCCA) is a rare malignancy which accounts for only 2-4% of all lower alimentary tract malignancies [1] . The incidence of SCCA has been rising and is now approximately 1.8 per 100,000, accounting for[7000 men and women per year in the US. Data from Public Health England show that the incidence of SCCA increased 126% in women and 69% in men in the UK during the period 1990-1994 to 2006-2010 [2] .
Due to its rarity, few high-quality randomised controlled trials are available to guide our decision-making. SCCA generally presents as a localised disease with a low risk of metastatic disease unless CRT fails. Locoregional failure is the predominant pattern of relapse [3] and is responsible for most SCCA-related deaths, making local control (LC) the primary aim of treatment and the primary endpoint in some trials. Overall survival (OS) has usually been a secondary endpoint in the trials. OS may not, however, be the most useful endpoint because OS requires large numbers of patients for sufficient events (such large numbers of patients with rare cancers are even more difficult to recruit), and there are competing risks of death in an elderly population. Also, the availability and feasibility of subsequent effective and specialist surgical salvage have not been uniform. These observations partly explain why the overall 5-year survival appears very similar in trials: 78% in the MMC arm of the Radiotherapy Therapy Oncology Group RTOG 98-11 trial [4] , 71% in the CRT-alone arms of the Action Clinique Coordonnées en cancérologie Digestive (ACCORD-03) [5] and 79% in the MMC arm of the Anal Cancer Trial (ACT II) [6] . Preservation of the anal sphincter is achieved in the majority, although with doses of 50-60 Gy (as used in the phase III trials),
anorectal function is often impaired [7] . The outcomes for patients with larger cT3/T4
cancers are less favourable. In the RTOG trial, patients with cT2/T3N0 had a 5-year disease-free survival (DFS) of 70%, which fell to 38% for cT3N1-3 and only 31% for cT4N1-3 [8] . In ACT II, patients with cT3/T4 cancers and/ or nodal metastases had a 3-year progression-free survival (PFS) of 63% [6] (see Table 1 ).
The randomised trials involving SCCA patients examined three cytotoxic agents as radiotherapy partners (5-fluorouracil, mitomycin C and cisplatin). Although the schedules are similarly timed (often days [1] [2] [3] [4] [5] and days [29] [30] [31] [32] [33] , the number of doses and the total mg delivered in these regimens have not been consistent ( Table 2 ). CRT using 5-FU and
MMC, which has been tested in several randomised trials [6, [9] [10] [11] [12] , is the standard of care which results in a high level of disease control for cT1/T2 cancers and is currently recommended in European and US guidelines [13, 14] . Although there is a clear need for more effective treatments in more advanced cT3/T4 and/or node-positive cancers, additional strategies examined in trials have so far failed to improve outcomes, in part because the CRT component was not always optimised.
Randomised phase III trials by the RTOG 98-11 [12] , the ACCORD-03 phase III trial [5] and the ACT II trial failed to show any additional benefit in terms of PFS by increasing the radiotherapy boost dose, or replacing MMC with cisplatin during CRT [6] . Nor has additional cisplatin-based chemotherapy given as induction prior to CRT [5, 12] or as maintenance chemotherapy after CRT [6] improved outcomes.
There have been some intriguing developments in the past 3 years in terms of our understanding of the molecular biology and processes which lead to SCCA, and the vital role of the immune system. There have also been some notable successes in prevention, imaging (e.g. MRI for staging delineation and restaging) and treatment. This paper will discuss these This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
EPIDEMIOLOGY AND PATHOGENESIS
The incidence of SCCA has been increasing over the past three decades-most markedly in women. The natural history is usually slow, with patients complaining of symptoms for months if not years, and distant metastases are uncommon at presentation [10, 15, 16] .
Hence, SCCA is usually amenable to locoregional CRT, which is a potentially curative treatment.
Risk Factors and Aetiology
The role of human papillomavirus (HPV) in the aetiology of SCCA was described more than 20 years ago [17] . SCCA is associated with HPV in 80-90% of cases [18, 19] Transplant recipients have a tenfold risk compared to the general population. Social deprivation is implicated [21] . A history of receptive anal intercourse increases the risk, but is not a necessary condition. Cigarette smoking is a potent risk factor [22, 23] .
Cigarette smoking may also have a role in the persistence of HPV infection, and potentially influences outcomes from treatment. Even in the context of HIV, patients with SCCA who smoke also appear to have a worse overall survival than nonsmoking patients [24] . Although previously discounted, recent data also suggest that there is a higher incidence of SCCA in Crohn's disease, an earlier age of presentation and poorer outcomes [25] . There is no clear association with any dietary habits or the presence of haemorrhoids [26, 27] . Men who have sex with men (MSM) have a high incidence of SCCA:(35 per 100,000, which increases to 75-135 per 100,000 with HIV seropositivity. The incidence is also higher among HIV-seropositive women [28] .
Substantial evidence implicates HPV in the aetiology of SCCA. HPV has been identified in 84 .5% of cases in a meta-analysis examining HPV prevalence in AIN and SCCA from 93 studies conducted in four different continents [18] . HPV16 and HPV18 appear to be the two commonest genotypes detected. Prospective data also link HPV seropositivity to the risk of subsequent SCCA [29] . HIV-positive and 
PRESENTATION AND DIAGNOSIS

Presentation
A mean age between 60 and 70 years is reported in European studies [10, 11, 59 , 60], but is typically a decade younger in studies from the USA [12, 61, 62] , which partly reflects the inclusion/noninclusion of patients with HIV.
One of the commonest presenting symptoms in SCCA is rectal bleeding, which can delay diagnosis because bleeding is often attributed to haemorrhoids. The saying ''nearly every lesion around the anus is liable to be called 'piles' by the patient and not infrequently by the referring doctor also'' remains relevant [63] .
Other common presenting symptoms include pain, anal discharge, an unpleasant fishy odour, pruritus ani and ulceration. Once the anal sphincters are involved, patients complain of soiling and then frank faecal incontinence with occasional fistula formation. Often the patient is aware of a lump. Occasionally patients present with enlarged inguinal lymph nodes in the absence of anal symptoms.
Anatomy and Lymphatic Drainage
The anal canal is approximately 3-5 cm in length, depending on the sex of the patient. It starts inferiorly at the anal verge representing the lowermost edge of the sphincter muscles. The anal margin extends from this anal verge and is considered the perianal skin with a 5 cm radius. The most proximal (i.e. superior) portion of the anal canal drains to perirectal nodes in the mesorectum and nodes along the superior rectal vessels to the inferior mesenteric system, and thereon to the paraaortic nodes, with additional drainage to the internal iliac and obturator nodes.
In tumours arising above the dentate line, drainage is via internal pudendal nodes to the internal iliac system. The upper half of the canal drains mainly by the superior rectal vein to the inferior mesenteric vein, while the lower half drains via the inferior rectal vein. Hence, metastases may occur either to the liver via the portal system or the lung via the systemic circulation, depending on the height of the tumour. Below the dentate line, drainage is to the superficial inguinal nodes, femoral nodes and external iliac nodes. The most frequent sites for nodal metastases are inguinal, femoral and iliac lymph nodes [64] . Clinically palpable (inguinal) lymph nodes are found in 16-25% of cases [12, 59, 65] . Fewer than 5% have distant metastases at presentation [10, 59, 62] .
Histopathology
Histological confirmation is mandatory prior to treatment, as other histological entities are possible in the anal canal. The biopsy specimen should be assessed to document the size of the tumour in terms of the greatest dimension in mm in all possible planes, and to comment on the resection margins at depth and at the periphery to decide if further treatment is required, particularly for tumours excised at the anal margin, which behave more like skin cancers. However, this may prove impossible if a piecemeal resection has been performed.
In the past, high-grade tumours were expected to be associated with a worse prognosis, but multivariate analysis in the randomised trials has not confirmed this view. Tumours of the anal margin are usually well differentiated and seen in men, but canal tumours are often poorly differentiated and more common in women; however, many view histological grading as subject to considerable interobserver variability and to be of limited prognostic value [66] . There is also heterogeneity observed in larger tumours. Histological subclassifications of basaloid, transitional, spheroidal and cloacogenic cell cancers no longer influence management [13] , although some authors retrospectively report that a basaloid histological subtype confers a higher risk of developing metastatic disease [67] . Verrucous carcinoma represents a further variant, which is sometimes described as a giant condyloma or Buschke-Lowenstein tumour.
Prognostic Factors
Recognised prognostic factors for SCCA are based on standard clinical and biological features, consisting mainly of TNM stage, site of disease, performance status, comorbidities, smoking history and molecular markers such as HPV/p16 status (see below). The clinical factors elicited from the randomised trials are summarised in Table 3 . However, even when patients are categorised according to these parameters, there are still considerable differences in behaviour, response and outcome. In future, advances in molecular biology and genomic technologies may allow the identification of different genomic and epigenomic patterns developing during tumour progression, and offer greater individualisation in the choice of treatment.
Molecular Biomarkers
A prognostic biomarker informs regarding the overall outcome for the patient, irrespective of the treatment to be given. In contrast, a predictive biomarker informs regarding the likely effect of a specific therapeutic intervention. Analysis of molecular differences between a large number of tumour specimens could identify such biomarkers, allowing the tailoring of treatment to individual patients and possibly the identification of new therapeutic targets.
Prognostic Biomarkers
Squamous cell carcinoma antigen (SCCAg) is a serum tumour marker expressed by SCCA which correlates with initial tumour stage and/or nodal status [68] . We have found this marker to be useful in complementing the initial staging and target delineation for radiotherapy, but its clinical utility in diagnosis, prognosis and follow-up remains controversial [69] .
In an attempt to distinguish the relative risk CEA), Hedgehog signalling, and telomerase [71] . The tumour-suppressor genes p53 and p21 were the only biomarkers demonstrating prognostic value in more than one study. 
Degree of differentiation Yes
Overexpression of p53 is common in anal carcinomas [72, 73] and helps to regulate the cell cycle and apoptosis. Inactivation of p53 leads to dysregulation of key cellular events [73] and may result from either mutations in its gene or sequestration by other cellular proteins, such as the E6 viral oncoprotein of the HPV virus [74] . In an unpublished analysis using samples collected from 240 patients randomised within the UKCCCR ACT I SCCA trial [10], the presence of mutated p53 predicted a poorer cause-specific survival in both arms [75] .
Predictive Biomarkers
In a small study of 30 patients treated with CRT, examination of biomarkers related to chemotherapy and/or radiation resistance suggested on multivariate analysis that Ki67, nuclear factor kappa B, sonic hedgehog, and nuclear Gli-1 are potentially associated with DFS [76] .
A recent report explored potential biomarkers with the aim of identifying novel treatment strategies [77] . SCCA specimens were tested via a multiplatform profiling service consisting of gene sequencing, protein expression by immunohistochemistry (IHC) and gene amplification (by CISH or FISH). This study demonstrated frequent expression of resistance-conferring proteins, i.e. multi-drug resistance-associated protein 1 (MRP1); excision repair cross-complementing gene 1 (ERCC1), which confers resistance to platinum-based chemotherapy; and thymidylate synthase (TS), which has a role in fluoropyrimidine resistance [77] . In contrast, the same study identified a number of targetable mutations which occurred with low frequency.
p16INK4A (p16): Prognostic and Predictive
Cell cycle progression is unchecked via the activation of p16, a cyclin-dependent kinase inhibitor that functions as a checkpoint inhibitor. IHC for p16 has been used as a surrogate for HPV involvement. The analysis of HPV-DNA by either polymerase chain reaction or p16 expression can be used as an independent prognostic marker for both OS and DFS in patients with SCCA [78] [79] [80] .
p16 expression is associated with greater radiosensitivity in the tumour and possibly with favourable inflammatory responses, although other factors such as smoking modify the better oncological outcomes associated with p16?. However, using p16 expression as a predictive biomarker requires prospective validation in a clinical trial prior to entering routine use (or being used to stratify treatments in future trials).
In contrast, there is increasing recognition that patients with p16-negative SCCA, although uncommon [81] , often fail to respond to CRT [79] and generally have worse outcomes following CRT. Relapse-free rates in p16-cases are worse than in p16? cases [78, 79, [82] [83] [84] . Rates of p16 positivity range from 65% [83] to 93% [78] , so the majority of relapses still occur in p16-positive patients. The more favourable prognosis for p16? partly reflects intact apoptotic machinery in the cell and low rates of p53 mutation [71, 79] , which maintains the response to CRT. The above information suggests that different management strategies/regimens are probably required for tumours which are p16 negative and thereby more difficult to control with standard CRT schedules.
In oropharyngeal cancers, a high circulating neutrophil count is associated with an inferior RFS and poor OS, but this effect seems to be limited to patients with p16-positive cancers [85] . In a small retrospective study of 92 patients with SCCA, an elevated neutrophil:lymphocyte ratio (NLR) was associated with worse overall (p\0.0001) and cancer-specific (p\0.0001) survival [86] .
Tumour-infiltrating lymphocyte scores can also be used to stratify p16? cases even further in terms of the risk of relapse [87] . Hence, in HPV?/p16? SCCA, both the systemic (NLR) and the local inflammatory environment, such as tumour-infiltrating lymphocytes (TILs), may influence clinical outcomes.
Staging and Initial Assessment
Staging information is useful for determining prognosis but also informs the clinician on the optimal management (i.e. systemic or local) and the choice of treatments. The information is also required by the radiation oncologist to delineate gross tumour volume (GTV) and contour the appropriate nodal and elective volumes. The risk of recurrence may also determine the most appropriate radiotherapy dose and the intensity of follow-up. The unified American Joint Committee on Cancer/ International Union Against Cancer (AJCC/ UICC) staging system incorporates primary tumour size (T), lymph node status (N) and distant metastases (M). The 7th edition of the AJCC/UICC classification for SCCA is shown in Table 4 [88] .
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AJCC Cancer Staging Manual, 7th edition (2010) metastatic disease that CT scan fails to detect, and alters staging in 42% of patients [90] . PET/CT also has utility in radiation therapy treatment planning as it facilitates the delineation of metabolically active areas, but with poor anatomical definition.
Lymph Nodes
The risk of inguinal nodal involvement is low if the primary is small [91] , but approaches 20% in cT3 or T4 cancers [92] . It should be borne in mind that[50% of involved lymph nodes will measure\5 mm. Fine needle aspirate cytology (FNAC) of groin nodes can also be helpful.
Sentinel lymph node biopsy (SLNB) can reveal the micrometastatic spread of disease in normal sized lymph nodes, and hence may be more accurate than conventional diagnostic imaging with MRI, CT and PET/CT, but it remains to be validated. A review of five small published series (83 patients) evaluated SLNB in normal-sized inguinal nodes in SCCA [93] . Nodal metastases were found in 7-42% of cases, and no serious complications were reported. A different review showed more favourable results and identified inguinal metastases in 13/63 patients (20.6%) with no false-negative nodes [94] . However, we are not yet in a position to stratify treatment according to macroscopic nodal involvement, microscopic involvement or the presence of a few isolated cells found on SLNB.
Prior to the use of intensity-modulated radiotherapy (IMRT) (which has been shown to reduce acute toxicity), there was a rationale for SLNB to spare formal inguinal irradiation, thereby reducing skin morbidity and damage to the femoral heads. The precision of IMRT means it is possible to contour these areas as organs at risk (OARs) and spare them. The risk of metachronous inguinal node metastasis in patients treated with prophylactic groin radiation appears low (4%) [61] . The most useful role of SLNB lies in identifying nodes in patients with locoregional recurrence after CRT so as to decide whether radical inguinal dissection is required at the time of salvage 
Optimising Radiotherapy
In the past two decades, trials have refined radiotherapy techniques and proved the efficacy of relatively low total radiation doses.
IMRT is considered the current standard. However, the optimal schedules, target volumes and radiation dose remain under debate and continue to be examined in clinical trials.
Field Size
Relapse can recur either at the primary tumour site, in the regional lymph nodes, or at distant sites. Evidence for the optimal RT dose and fractionation is limited by a lack of data regarding the pattern of failure. No randomised study has published detailed data describing the topography and sites of local failure (within, marginal to, or outside of the radiotherapy field). Preliminary data from the ACT II trial suggest the majority of locoregional failures occur in-field [96] 
Neoadjuvant or Induction Chemotherapy
The design of the Intergroup trial RTOG-9811 was based on the results of a successful phase II trial [113] . Induction chemotherapy resulted in 8 CR and 21 PR in the 44 evaluable patients.
Only a single patient progressed. Following CRT (which included a mandated 3-week gap) there was a CCR rate of 82%. Overall, 16 patients had persistent (n = 8) or subsequent locally recurrent (n = 8) disease [113] .
These encouraging results led to the development of the RTOG9811 trial, which used the induction regimen as the experimental arm but did not use mitomycin (as an additional potentially non-cross-resistant component)-it was replaced by cisplatinmaking a total of 4 courses of 5-FU/cisplatin [12] . This different novel arm was compared with the standard 5-FU/MMC CRT, but the CALGB study may have raised the acceptance that a gap was not disadvantageous and could be an acceptable treatment strategy.
Induction chemotherapy (ICT) using cisplatin failed to improve OS, DFS, locoregional control and distant relapse when compared to the standard arm. Results after a median follow-up of 2.51 years showed that the 3-and 5-year DFS rates were 67% and 61%, respectively, in the MMC arm, versus 61% and 54% for the cisplatin arm. The 3-and 5-year OS rates, at 84% and 75% for the MMC arm compared to 76% and 70%, respectively, for the cisplatin arm, were not significantly different (p = 0.1) [12] . Interestingly, the results for the CALGB trial parallel those in the RTOG 9811 trial, but in the RTOG 9811 trial, only 26% of the patients had tumours greater than 5 cm, and 26% had positive nodes.
In contrast, the CALGB trial restricted the eligibility to stage cT3/T4 or lymph node involvement (cN2/N3) [113] .
Finally, the ACCORD-03 phase III trial [5] randomised 307 patients in a factorial 292 trial design between 2 cycles of induction chemotherapy (ICT) with 5-FU and cisplatin and secondly a radiation dose escalation. With a mean follow-up of 50 months, the results did not show any benefit of ICT compared to standard treatment [5] , probably because a 21-day interval was mandated between the main CRT schedule and the boost.
Consolidation/Maintenance
Chemotherapy Following Chemoradiation
The addition of consolidation chemotherapy after CRT is intended to increase efficacy. An early pilot of this strategy in which three cytotoxics were added to radiotherapy in a CRT schedule and also administered as consolidation proved too toxic to consider for a phase III trial [114] . Despite these results, a two-drug maintenance chemotherapy schedule using 5-FU and cisplatin was adopted in the ACT II phase III trial on the basis of this pilot study, i.e. 2 courses of 5-FU 750 mg/m 2 for 4 days and cisplatin 60 mg/m 2 on days 71 and 98 (i.e. 11 and 14 weeks from start of treatment) in a second randomization as consolidation. In the ACT II trial there was no significant benefit for consolidation/maintenance chemotherapy [6] in terms of achieving cCR or reducing tumour relapse or cancer-specific deaths compared to the standard arm using MMC/CRT. 
SURVEILLANCE AND SALVAGE SURGERY
Response Assessment
There is debate regarding the safest time to In practice, persistent ulceration can raise suspicion of ongoing nonresponding disease, though definitive histology is usually required before submitting the patient to APR [119] .
Positron emission tomography at 1 month has also been advocated to assess clinical response [120] .
Nowadays, most wait for longer periods to allow assessment of regression. In the ACT II trial, complete clinical response (cCR)-i.e. complete absence of tumour and clinically node negative-was assessed by DRE or imaging at 11 and 18 weeks with a mandated CT at 26 weeks after the start of CRT. At week 11, 66% of patients achieved cCR with MMC and 56% with cisplatin, compared to 75% and 76% at 18 weeks and 83% and 84% at 26 weeks, respectively [6, 121] . So, whilst we would advise careful monitoring of the inguinal region and primary tumour after completion of CRT to facilitate timely surgical salvage for progression, it appears safe to observe a resolving tumour up to 26 weeks following the start of CRT.
Follow-up Surveillance
Following radical CRT, regression is recognised to be slow, and may take up to 6 months. were again T status and involved margin. This study achieved a 5-year overall survival of 60% [123] . Other previous studies have identified positive surgical margins, nodal involvement and perineural/lymphovascular invasion as factors associated with survival [124] . In a small study from Swansea, 11/96 (12%) required salvage surgery following CRT, five of whom were stage T4 at presentation. Six patients had failed to respond to CRT, and five presented with recurrence at a median of 10 (10-36) months [125] .
Since most locoregional recurrence occurs within the first 3 years following CRT [96] , some surgical groups have adopted a proactive approach with sequential surveillance CT or pelvic MRI to detect early relapse, taking the view that there may be a limited window of opportunity to resect a local disease relapse. In 
Late Effects
The majority of patients with SCCA are cured by CRT, and surgery can salvage at least 50% of local relapses. Hence, if patients survive long term, it is even more important to minimise late effects, which are infrequently reported and poorly recorded in phase III trials. There is a wide spectrum of effects, from minor persistent symptoms to life-threatening complications, but there is still no widely accepted classification for describing late morbidity of radiation. The WHO and RTOG/ECOG systems, used in the EORTC, ACT I and RTOG-8704 trials, were not specifically designed to capture radiation-induced morbidity.
The ACT I trial defined any toxicity occurring or persisting more than 6 months after completing initial radiotherapy as late morbidity. Toxicity was not scored or quantified [3] but simply described, and was more common in the subgroup who received boost by implant (14%) compared with an EBRT boost (6%; p = 0.003), although post-treatment biopsies for suspicion of residual disease might have contributed in some to nonhealing and ulceration. The ACT II trial collected regular descriptive reports of the presence or not of a range of late effects (bowel, urinary and sexual) which were considered by the investigator to be severe but were not formally graded according to the RTOG scale. However, many patients have severe G3/G4 late effects [126] , and up to 20% historically required a colostomy for these adverse late effects alone [127] .
Long-term colostomy rates vary from 15% to 36% in the randomised trials [10, 11] and population studies [59], of which approximately 10% are fashioned initially for symptom control. Most of these are never reversed. In addition, 10-15% of colostomies are required to deal with the consequences of treatment [3, 12] . In the RTOG-9811 trial, the rate of severe long-term toxic effects was similar in both arms, 11% vs. 10%, but only 5% required a colostomy for treatment-related problems.
Hence, nurse-led clinics promoting survivorship in patients who have received pelvic radiotherapy are gaining support [128, 129] . These identify late effects, enabling therapeutic interventions and counselling to reduce the psychosocial and physical impacts of such symptoms. There are also reports detailing the effectiveness of pelvic floor exercises and/or biofeedback training in patients who experience faecal urgency and incontinence.
Quality of Life
Effects of treatment on long-term quality of life (QOL) in patients with SCCA based on data within the published randomised trials have not been published, partly due to the absence of an available validated questionnaire specific to SCCA at the time of trial design. Preliminary data from ACT I [130] were presented in an abstract only. In the ACCORD-03 study, an early assessment at 2 months after completion of CRT did not
show that NACT and high-dose radiotherapy, either alone or in combination, had a negative impact on quality of life [131] . In fact, QOL appeared to be better than the QOL defined at entry prior to CRT.
Retrospective analysis of long-term QOL suggests there is a high rate of faecal incontinence [7, 132] sexual problems in both males and females as well as financial difficulties, even 5 years later. However, some studies seem to demonstrate that QOL is satisfactory to patients despite an objective impairment of sphincter function [133, 134] . There has been a recent systematic review on this topic [135] . Currently, a specific EORTC anal cancer module is being developed to replace several other modules that are frequently used-EORTC QLQ-C30 and-CR29 (colorectal cancer), EORTC QLQ-PRT23 (for radiation proctitis) and EORTC QLQ-PR25 (for prostate cancer)-to include all QOL issues relevant and specific to anal cancer, and with a focus on pelvic toxicities and stoma placement.
TREATMENT OF METASTATIC DISEASE
Carcinoma of the anus rarely spreads outside the pelvis unless the primary tumour is unresponsive to chemoradiation or local failure is observed. Distant disease at presentation is reported in less than 5% of cases, and usually involves para-aortic nodes, lung, liver or bone.
Although single-agent carboplatin has been examined, the combination of 5-FU and cisplatin remains the most commonly used palliative regimen, and it is the only regimen recommended in the NCCN guidelines [14] .
Response rates of 20-60% are reported when this regimen is used as the first-line therapy, but such rates are rarely sustained. 
NEW DIRECTIONS
Intensity-Modulated Radiotherapy
Technical advances in radiation oncology such as IMRT allow better precision with adequate doses of radiotherapy to the tumour while sparing sensitive normal surrounding structures such as perineal skin, the external genitalia, the bony confines of the pelvis (sacrum and pubis), the femoral head and neck, the bladder and the small bowel. IMRT also offers the potential for dose escalation of the radiotherapy. IMRT appears most useful in tumour sites with a marked dose-response curve (such as prostate cancer and head and neck cancer) or that are close to critical organs.
The ACT II trial used low doses to treat the nodes electively in the first phase of treatment (30.6 Gy in 17 daily fractions), which successfully prevented disease at these sites [6] .
There is further retrospective support for the efficacy of a low-dose (36 Gy) elective nodal irradiation [136] . The differential doses required for elective nodal irradiation and the gross primary/nodal tumour favour the use of IMRT.
The shapes of the lymph node targets in the pelvis are predominantly concave, and it is difficult to spare normal tissue using 3D-CRT techniques. With IMRT or rotational IMRT using highly modulated dose fluence from multiple directions, we can limit the high-dose volume outside the treatment target, reducing the dose to OARs and thereby modifying acute and late toxicity.
Sparing the anal canal is difficult, and the maximal dose to the sphincters may predict the risk of complications. There is limited evidence regarding long-term function, but the maximum dose to the anal canal has been recommended by some to be only 55 Gy [137] .
A multicentre study of IMRT [138] reduced acute grade 3 toxicity and still maintained good LC. Further data from this study showed that the volume of bowel receiving 30 Gy V(30) correlated with acute gastrointestinal (GI) toxicity in chemo IMRT-treated SCCA patients.
Similarly, IMRT treated elective pelvic regions and inguinal nodes (to 45 Gy) but reduced the volume of pelvic bone marrow receiving 15 and 20 Gy (PBM-V15 and PBM-V20), which appears to affect the absolute nadir neutrophil count (ANC) [139] . This sparing of normal tissues may allow improved compliance and maintains a short OTT. Late morbidity is likely to be reduced, albeit at the price of more second malignancies because of the wide-field low doses.
Biological Agents
EGFR Inhibition
EGFR is overexpressed in up to 90% of SCCAs [140] [141] [142] , and EGFR, K-RAS or BRAF mutations are rarely identified [141, [143] [144] [145] [146] , although one study showed that PIK3CA was mutated in 22% of cases [145] . Pre-clinical studies suggest that inhibiting EGFR signalling slows cell proliferation in vitro and in vivo and promotes additive effects with radiotherapy [147] . EGFR contributes to tumour development and progression through autocrine stimulation of cell proliferation. In addition, radiation itself induces EGFR activation, which contributes-at least in part-to the mechanism of accelerated proliferation, and can be expected to increase the capacity for tumour DNA damage repair. Overexpression of epidermal growth factor receptor (EGFR) has been linked to radioresistance [148, 149] .
A landmark phase III study in patients with locally advanced squamous cell head and neck cancer [150] showed that cetuximab (a recombinant, chimeric monoclonal antibody directed against the epidermal growth factor receptor) in combination with radical radiotherapy significantly improved overall survival compared to radiation alone. Hence, there may be a therapeutic role for agents causing EGFR inhibition in SCCA either as a single agent with radiation or in combination with standard CRT.
In SCCA, several small studies have evaluated the combination of 5-FU, cisplatin and cetuximab with radiation. In a Brazilian study [151] , 23 patients were enrolled, butdespite a response rate of 95%-the study was closed early due to toxicity, including 6 (26%) episodes of thrombosis and embolism, 12 (52%) cases of severe grade 3-4 radiation dermatitis and 10 (44%) cases of grade 3-4 diarrhoea.
The ACCORD 16 phase trial also evaluated cetuximab in combination with CRT using 5-FU, cisplatin and 45 Gy of RT, but it too closed early because the authors concluded that the toxicity was unacceptable [152] [151, 152] , although it may reflect differences in the radiation dose, the field size or the patient population.
Finally, a recent phase I study employed IMRT and combined cetuximab with 5-FU/ MMC-based CRT using a simultaneous integrated boost (SIB) administering 57.5/54.0/ 48.6 Gy in 27 fractions to primary tumor/lymph node metastases/adjuvant lymph node regions, respectively [154] . Toxicity was acceptable, and is insufficient evidence to recommend the use of cetuximab in concurrent CRT in SCCA (see Table 6 ).
Two further phase II studies (NCT01843452 and NCT01285778) are currently evaluating the benefit of the addition of panitumumab to CRT with capecitabine and mitomycin C. The Vital trial (NCT01285778) has finished recruiting patients.
PI3K/AKT/mTOR Pathway
The phosphatidylinositol 3-kinase pathway of cases with early-stage disease [157] . Interestingly, in non-small-cell lung cancer, current smokers are significantly more likely to However, it will be important to ensure these novel treatments do not impact adversely on acute toxicity and late function, which is likely to have a knock-on effect on colostomy-free 
